Collaboration

CURADIGM ANNOUNCES COLLABORATION WITH SANOFI AS PART OF THE SANOFI ITECH AWARDS PROGRAM

CURADIGM ANNOUNCES COLLABORATION WITH SANOFI AS PART OF THE SANOFI ITECH AWARDS PROGRAM

Curadigm, an early-stage nanotechnology company dedicated to improving treatment outcomes by shifting the therapeutic delivery paradigm, today announced the selection of its project for the Sanofi iTech Awards program with its proprietary Nanoprimer technology. The Sanofi iTech Awards program aims to identify external innovations with the potential to significantly improve drug discovery and design, drug delivery and drug development within Sanofi. […]

Continue Reading...

CURADIGM ANNOUNCES PUBLICATION OF RESULTS USING PROPRIETARY NANOPRIMER TO IMPROVE RNA THERAPEUTICS IN COLLABORATION WITH THE LANGER LAB

CURADIGM ANNOUNCES PUBLICATION OF RESULTS USING PROPRIETARY NANOPRIMER TO IMPROVE RNA THERAPEUTICS IN COLLABORATION WITH THE LANGER LAB

The data generated during this fruitful collaboration with Prof. Langer’s lab and published in Nano Letters are very important for Curadigm. it represents an external validation of our concept to address the unmet needs of nucleic acid - based therapeutics. The potential of the Nanoprimer to improve treatment efficacy by avoiding liver clearance is a great opportunity to accelerate the development of RNA-based therapeutics and to bring a real benefit for the patients. […]

Continue Reading...

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration

Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy, announced the selection of its Nanoprimer technology by the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) for characterization, based on its potential to significantly impact treatments in multiple disease indications, including cancer. […]

Continue Reading...